Gemin X Pharmaceuticals Inc., a firm that had been on the prowl for a partner after wowing Wall Street a couple of years ago with early stage data for small-cell lung cancer (SCLC) candidate obatoclax, was snatched up by Cephalon Inc. for $225 million up front.